Background: Pharmaceutical companies and other trial sponsors must submit certain trial results to ClinicalTrials.gov. The validity of these results is unclear.
S
ponsors are required by federal law to submit summary results of applicable clinical trials (including those beyond phase 1 supporting U.S. Food and Drug Administration [FDA] new drug approvals) to ClinicalTrials.gov for public posting (1) . Submissions consist of minimum "basic results" data elements in tabular format, including results for all primary and secondary outcomes prespecified in the study protocol and all anticipated and unanticipated serious adverse events observed during the trial (2) . This law also requires ClinicalTrials.gov to assess ways to verify the accuracy of sponsor-submitted results information, including using public sources, such as FDA advisory committee summary documents and FDA action package approval documents (3) . Although ClinicalTrials .gov currently determines internal consistency through quality checks (4) , the validity of posted results can be assessed only by comparing submitted data with external reference standards. Recent studies comparing ClinicalTrials.gov data with peer-reviewed journal publications suggest that discrepancies in reported primary and secondary outcomes, numerical results, and adverse events are relatively common, although which source is more likely to be correct is unclear (5) (6) (7) .
Drug approval packages from the FDA may represent a better "reference standard" than publications for validating results posted on ClinicalTrials.gov, because journal editors and peer reviewers typically lack access to individual-participant data. Consequently, investigators may choose to publish outcomes based largely on statistical significance or other criteria (8 -10 ). In contrast, FDA statisticians, who have access to individualparticipant data, can analyze sponsor-submitted trial results independently on the basis of what they believe are the best statistical practices (11, 12) . Independent analysis of individual-participant data from a trial may yield treatment effects that range in direction, magnitude, and statistical significance according to the particular outcome selected and how it is analyzed (for example, discretion in selecting measurement populations, such as intention-to-treat vs. per-protocol population; accounting for missing data; or timing for outcomes assessment). For example, on the basis of 6-month results, a high-profile journal article concluded that celecoxib reduced major bleeding compared with ibuprofen and diclofenac (13). However, the FDA reviews, which included results for the protocol-specified 1-year end points, indicated that celecoxib did not reduce major bleeding (14) .
We compared sponsor-submitted definitions and results posted on ClinicalTrials.gov with corresponding FDA-generated information posted on Drugs@FDA for trials used to support new drug approvals-specifically, how often efficacy and adverse event outcomes could be compared and whether posted data were consistent.
METHODS

Sample Collection
To identify 100 parallel-group, randomized trials that were the basis for FDA new drug approvals (that is, new molecular entities), we searched Drugs@FDA (15) beginning with approvals on 1 January 2013 (Figure) . Each FDA approval package includes review documents written by FDA staff (such as physicians, statisticians, and pharmacologists). These documents, which summarize analyses of clinical and other data submitted in new drug applications, are used by the FDA to determine whether to approve marketing of new drugs or biologic products for a particular use (16) . Although the FDA has made some drug approval packages and component review documents publicly available on Drugs@FDA since 1997 (12) , recent federal law now requires systematic posting of "action packages" for original new drug applications (1) .
We manually searched FDA medical and statistical reviews to find all trials designated as "pivotal" and "supportive" by the FDA reviewer. We then sought to match these trials with the corresponding results in ClinicalTrials.gov, downloaded on 15 March 2015. Although ClinicalTrials.gov and Drugs@FDA were created for different purposes, their content overlaps substantially ( Table 1) . Because FDA review documents do not list ClinicalTrials.gov identifiers (NCT numbers), we used the process described in the Figure to match trials between sources. We searched Drugs@FDA through July 2014 until reaching our target: 75 pivotal and 25 supportive parallel-group, randomized trials with some results data in both sources, comprising all trials that could be compared during this time frame. We hypothesized that documents available from Drugs@FDA would contain less results information for supportive trials than for pivotal trials, which provide the primary evidence for approval.
Data Extraction
We created a structured data extraction form to capture detailed trial information from ClinicalTrials .gov and Drugs@FDA and revised it after a pilot test extracting information for 5 trials. The 6 major domains (Appendix Table 1 , available at www.annals.org) were as follows: 1) trial characteristics, including drug indication, development phase, blinding, comparator, and basic trial data (number of patients randomly assigned, number of patients completing the study, age, and sex distribution); 2) primary outcome, including definition using the following framework: domain, specific measurement, specific metric, and method of aggregation (4) plus time frame, analysis (measurement population and methods to account for missing data), result values (consistency of number analyzed and results for each study group), and treatment effect (consistency in treatment effect and associated CI and P value between experimental and control groups); 3) secondary outcomes (number, data availability, and outcome); 4) serious adverse events (number analyzed and consistency of results); 5) deaths (whether they were reported or it was mentioned that no deaths occurred; consistency of results); and 6) number of other adverse events.
In contrast to ClinicalTrials.gov records, which typically present only a single set of analyses per outcome, Drugs@FDA review documents often present multiple analyses, including those conducted by the sponsor and separately by the FDA statistician (such as sensitiv- Two assessors systematically extracted, and another verified, the trial design, primary and secondary outcomes, adverse events, and deaths from both ClinicalTrials.gov and Drugs@FDA.
Data Comparison
Consistency of Outcome Definitions and Analyses
The number and definitions of primary and secondary outcomes posted on ClinicalTrials.gov (and concordance in outcome "level") were compared with those listed in Drugs@FDA. Definitions of primary outcome were considered discordant if a mismatch occurred at any level of the following framework: domain (such as anxiety), specific measurement (such as Beck Anxiety Inventory), specific metric (such as change from baseline), or method of aggregation (such as mean). We also used an alternative definition of discordance that excludes the method of aggregation to account for researchers who feel it is unnecessary to prespecify statistical analysis plans before trial unblinding (11). In addition, we compared timing of the outcome assessment plus 3 key aspects of the primary outcome analyses: measurement population, crude or adjusted analysis, and method of handling missing data.
Consistency of Results
We assessed the consistency of results reporting between ClinicalTrials.gov and Drugs@FDA using the approach adopted from Hartung and colleagues (7) (detailed in Appendix Table 1 ). For example, results for the outcome measure "change from baseline HbA 1c " (hemoglobin A 1c ) were considered discordant if the reported values were not consistent to 1 decimal place (for example, 0.094 is not consistent with 0.12 because it rounds to 0.09, but 0.115 would be consistent because it rounds to 0.12).
We analyzed the data at 2 levels: numbers of trials, and numbers of primary outcomes or named serious adverse events, including death. Although the latter approach explicitly shows the frequency of discrepancies for individual measures, it may overstate the distribution of discrepancies among trials, because the number of potential discrepancies is the product of the outcomes times the number of study groups. Reporting numbers of trials mitigates this problem-a few discordant trials (even with many outcomes) would not overwhelm most concordant trials. This approach, however, created an important challenge: How many discordant outcomes (or study groups) does it take to deem a trial "discordant" between the 2 sources? We used the Hartung approach and called a trial discordant if data from ClinicalTrials.gov and Drugs@FDA were inconsistent for 1 or more results; concordant if all were consistent; and "cannot compare" if, in both sources, the outcomes did not match or the data were not posted.
Role of the Funding Source
Drs. Woloshin and Schwartz were funded by a contract from the National Library of Medicine. Drs. Tse and Zarin were supported in part by the Intramural Research Program of the National Library of Medicine, National Institutes of Health. The funding sources had no role in the study design, study design, data analysis, reporting of the results, or decision to submit the manuscript for publication. 
RESULTS
Overall, our sample of 100 parallel-group randomized trials (90% phase 3) was used to support 32 recent new drug approvals from 24 pharmaceutical companies for various indications, most commonly diabetes (42%) and pulmonary disease (19%) ( Table 2) . Most trials were double-blind (92%) and included a placebo control (73%). Although trial results from both sources listed a median of 1 primary outcome measure (range, 1 to 8), the Drugs@FDA reviews listed a median of 5 (0 to 94) "key" secondary outcome measures, compared with a median of 7 "prespecified" secondary outcome measures (0 to 227) posted on ClinicalTrials.gov.
The numbers of trial participants randomly assigned and completing the trial were discordant in 24 and 31 trials, respectively, in which the median discrepancies were 2% and 13% as a proportion of the total number. Mean age was discordant in 4 trials but could not be compared for 27 trials, largely because the data were presented in different formats (for example, categories vs. means).
Primary Outcomes Measures and Outcomes
Primary outcomes largely were consistent between both sources ( Table 3) . Of 137 primary outcomes posted on ClinicalTrials.gov, Drugs@FDA mentioned 134 (98%) (among which only 4 had discordant out- 
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Results Reporting in ClinicalTrials.gov and Drugs@FDA come definitions) and concordantly specified 119 (87%) as "primary." Table 4 illustrates 2 types of discrepancies observed between ClinicalTrials.gov and Drugs@FDA primary outcomes. The first type of discrepancy occurred for outcomes specified as primary in both sources with discordant definitions. The 4 cases of discordance based on the broader definition stemmed from differences in the use of measurement tools (1 case), methods of aggregation (2 cases), and time frames (1 case).
(Using the narrower discordance definition, we observed only 2 cases.)
The second type of discrepancy occurred for ClinicalTrials.gov primary outcomes that Drugs@FDA did not specify as primary ( Table 4) . Of the 14 cases, Drugs@FDA did not mention the outcome at all in 3 and mentioned it, but did not specify it as primary, secondary, or tertiary, in the remaining 11. Ten of these discrepancies occurred in 8 trials in which at least 1 other ClinicalTrials.gov primary outcome also was identified as primary in Drugs@FDA. For example, for a trial of mipomersen (Kynamro [Genzyme]) for hyperlipidemia (NCT00607373), ClinicalTrials.gov and Drugs@ FDA matched on the primary outcome "% change in LDL" (low-density lipoprotein), but ClinicalTrials.gov listed another primary outcome ("mean LDL at the end of the study"), which appeared without any specified level in Drugs@FDA.
In 3 of the 100 trials, none of the ClinicalTrials.gov primary outcomes was considered primary by the FDA. For example, for a trial of pomalidomide (Pomalyst [Celgene]) for multiple myeloma (NCT00833833), ClinicalTrials.gov listed 3 primary outcomes, none of which matched a Drugs@FDA-specified primary outcome. The first ClinicalTrials.gov-listed primary outcome, dose-limiting toxicity from phase 1 of the trial, was not mentioned in the available FDA documents. The FDA deemed the second ClinicalTrials.gov-listed primary outcome, progression-free survival (time-toevent analysis), "exploratory," stating that objective response rate (not specified as either a primary or secondary outcome in ClinicalTrials.gov) should be primary. The third ClinicalTrials.gov-listed primary outcome, percentage of patients with disease progression or death, was mentioned in the FDA documents but without a specified outcome level. The other 2 trials in which no primary outcome matched investigated obinutuzumab (Gazyva [Genentech]) for chronic lymphocytic anemia (NCT01010061) and empagliflozin (Jardiance [Boehringer Ingelheim]) for diabetes (NCT01167881).
Two analytic methods for the primary outcome, measurement population and whether results were crude or adjusted, were discordant for 9% (12 of 129 with data in Drugs@FDA) and 5% (7 of 129), respectively, of primary outcomes and could not be compared for 10% (13 of 129) and 6% (8 of 129) ( Table 3) . One notable discordance occurred in the second pivotal trial testing ospemifene (Osphena [Shionogi]) for dyspareunia in postmenopausal women (NCT00276094)-the ClinicalTrials.gov record reported an analysis of the full randomly assigned population for 3 of the 5 primary outcomes, but the information on Drugs@FDA presented only the analysis for the subgroup for whom the drug had a benefit (that is, women with dyspareunia as their most bothersome symptom). Although 51% of primary outcomes had concordant descriptions of how missing data were handled, 47% could not be compared because of missing information in at least 1 Among the 100 trials, the number of persons analyzed for the primary outcome was discordant in 23 trials and the results were discordant for 14 (in addition, 8 were not reported in either or both sources) ( Table 5) . Of 137 ClinicalTrials.gov-listed primary outcomes, 42 (31%) were discordant in the number of persons analyzed and 22 (16%) had discordant results. Discordance was not even among the 24 drug companies (Appendix Table 2 , available at www.annals.org). For 6 companies listed as lead sponsors on ClinicalTrials.gov, at least half of the primary outcomes across the trials sponsored by each were found to be discordant for either the number of patients analyzed or the results: BioMarin (1 of 1 discordant for results), Genzyme (4 of 8 discordant for number [of patients] analyzed), Iroko (2 of 3 for results), Shionogi (13 of 13 for number analyzed and 8 of 13 for results), Takeda (6 of 12 for number analyzed), and Trius (1 of 2 for number analyzed). As hypothesized, fewer results were presented for supportive (n = 4) than pivotal (n = 24) trials in documents available on Drugs@FDA.
Treatment effects, corresponding CIs, and P values could not be compared in about one third of the cases because the information was not available in 1 or both sources (for example, treatment effects were not available in either or both sources for 26% of trials and 35% of primary outcomes). When treatment effect sizes were included in both sources, few trials (n = 5) had discordant results-all relative differences were less than 10%.
Secondary Outcomes
Drugs@FDA lists only the secondary outcome measures considered key for regulatory decision making by FDA reviewers, thus limiting our ability to validate ClinicalTrials.gov entries. Of the 1927 secondary outcomes on ClinicalTrials.gov, Drugs@FDA mentioned 1061 (55%) and specified 981 (51%) as secondary; results were included in Drugs@FDA for 367 (19%) ( Table 3) .
Harm Reporting
Documents in Drugs@FDA frequently pooled serious adverse events across trials to support the overall assessment of harm for a drug. Our sample included 14 trials for which Drugs@FDA documents listed trialspecific serious adverse events that were also included in ClinicalTrials.gov (Table 5) . Among these trials, the number of unique named events reported per trial was substantially greater at ClinicalTrials.gov (median, 50; range, 1 to 223) than Drugs@FDA (median, 9; range, 1 to 37). Serious adverse event results were discordant (with respect to the number of people experiencing them) in 7 of 14 trials. Drugs@FDA recommended a sensitivity analysis with alternate definition (i.e., using the most severe rather than the majority pathology reading for disagreement) Endometrial hyperplasia
Endometrial hyperplasia Matched primary outcome
HbA 1c = hemoglobin A 1c ; LDL = low-density lipoprotein. * Outcomes that were primary in both sources with discordant definitions (n = 4 primary outcomes) and ClinicalTrials.gov primary outcomes that were not identified as "primary" in Drugs@FDA (n = 14 primary outcomes). Concordant outcomes for trials with ≥1 concordant primary outcome are shown in boldface.
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A total of 62 trials listed at least 1 death in either or both sources. Of the 25 trials that reported the number of deaths in both sources, 17 (68%) were discordant. For 15 of the 17 discordant results, fewer deaths were reported in ClinicalTrials.gov. Some but not all discrepancies stem from time frame differences. The largest discrepancy (104 deaths) was seen in a pivotal trial of radium-223 dichloride (Xofigo [Bayer]) for hormoneresistant prostate cancer (NCT00699751). The ClinicalTrials.gov record reported 6 deaths, assessed "after the first injection of study treatment and within 12 weeks after the last injection of study treatment." The Drugs@FDA documents, however, noted 110 deaths: 30 occurring during the treatment period (that is, between first and last injection) plus 30 days and another 80 in the next 3 years. The time frame difference cannot entirely account for the discrepancy, because more deaths occurring over less time were reported in the Drugs@FDA documents than on ClinicalTrials.gov.
DISCUSSION
We matched almost all the primary outcome measures posted on ClinicalTrials.gov with publicly available data from Drugs@FDA in our sample. The primary outcome definitions and results listed in the ClinicalTrials.gov entries were largely consistent with those reported in corresponding review documents from Drugs@FDA. A few, however, were nominally discordant. In 3 of the 100 trials examined, no ClinicalTrials.gov-listed primary outcome matched any primary outcome identified on Drugs@FDA, raising questions about the correctness of these ClinicalTrials .gov entries. Thus, our analysis suggests that Drugs@ FDA may be a useful resource for validating primary outcomes posted on the ClinicalTrials.gov results database, but manual extraction from Drugs@FDA and matching of trials and primary outcomes between the 2 databases required considerable effort.
In contrast, Drugs@FDA was not as helpful in validating secondary outcome measures, adverse events information, and death. Only about half (51%) of the secondary outcomes listed in ClinicalTrials.gov were Our analysis highlights mismatches in primary and secondary outcomes, which illustrate the different purposes of the 2 databases: ClinicalTrials.gov contains sponsor-submitted results with a focus on fidelity to the protocol as required by law for public posting, and the information at Drugs@FDA focuses on FDA-analyzed results for regulatory decision making. In some cases, the sponsor's protocol may have been written without FDA input-or even in contradiction to FDA recommendations regarding design or analysis (17, 18) . Consequently, analyses by FDA staff may deviate from the sponsor's prespecified plan if the FDA believes that there is a better way to analyze the data to inform its regulatory decisions (11).
Our study has several limitations. We analyzed only parallel-group, randomized trials, so whether our findings generalize to other designs that may be the basis of FDA approval (such as uncontrolled or crossover studies) is unclear. Further, although we cannot be certain that our sample is sufficiently representative of all trials used to support new drug approval, the analyzed trials are unselected, recent FDA new drug approval trials with results reported on ClinicalTrials.gov and cover a broad array of drug products and indications. In addition, the study characteristics reported in Table 2 seem consistent with previously reported analyses of trials supporting FDA new drug approvals (19, 20) . Nevertheless, our sample included only 24 drug companies, and discordance was concentrated mostly among a few (Appendix Table 2 ).
This study also highlights important limitations of both databases as public resources. ClinicalTrials.gov would be improved by further clarifying key definitions and by providing additional structure to certain data elements. For example, most prespecified secondary outcome measures reported in ClinicalTrials.gov are identified as something other than key (such as "exploratory" or "safety") by FDA reviewers, raising questions about the meaning of the term as generally understood. The recent notice of proposed rulemaking issued by the U.S. Department of Health and Human Services proposes reserving the term secondary for prespecified outcomes with a statistical analysis plan (outcomes not primary or secondary would be designated as exploratory)-and all submitted outcome definitions would need to specify the measurement, metric, method of aggregation, and time frame (21) . This might help prevent the cherry picking of result-driven false positive findings that pervades the published biomedical literature (8 -10) . The notice also requests comments on whether to require the submission of full protocols to ClinicalTrials.gov, which some have suggested would reveal how secondary outcomes prospectively were defined and intended to be analyzed (22, 23) . Others have noted that greater structuring of ClinicalTrials.gov (24), such as separate data elements for measurement population, handling of missing data, and all-cause mortality (6), would improve the utility of results reporting, albeit with an added burden on data submitters.
The utility of Drugs@FDA for validating Clinical Trials.gov entries specifically, and for third-party researchers in general, would be improved if NCT numbers were included to provide unambiguous identification of trials and if greater structure were provided (12) . For example, it was challenging to find the trials of interest unambiguously and to identify those sections of interest in the review documents. The FDA's new Drug Trials Snapshot Web site (25) makes primary outcome results more accessible but lacks a standard format for trial data and analytic methods.
ClinicalTrials.gov and Drugs@FDA, which are extraordinary resources that contribute to transparent communication of trial results, might complement each other in additional ways. ClinicalTrials.gov is an attempt to provide "fishbowl transparency," a complete reporting of all summary data according to the prespecified study protocol (26) . In contrast, Drugs@FDA, which reflects what the FDA believed was the proper analysis for regulatory action, provides a different kind of transparency, sometimes called "reasoned transparency" (26) , or guidance and context for interpreting what lives in the fishbowl based on the independent opinions of the FDA's expert reviewers. Unfortunately, these opinions may be hard to find in review documents as currently formatted. Even if all the numbers reported in ClinicalTrials.gov were completely accurate, questions would remain about the trial design, conduct, or analysis, which may affect conclusions about the trial results assessed in Drugs@FDA. For example, reviewers may have raised questions about the appropriateness of an active comparator used (or its dose) or about unvalidated outcome measures. Implementing better integration between ClinicalTrials.gov and Drugs@FDA for providing context (for example, by including NCT numbers in Drugs@FDA documents) would help combine the fishbowl and reasoned approaches to transparency. The result would be better health information and, perhaps ultimately, better health. 
